UPDATE 1-Bristol's Opdivo proves effective against second type of lung cancer

April 17, 2015 2:35 PM

10 0

April 17 (Reuters) - A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications.

The U.S. drugmaker on Friday said the study, called Checkmate-057, was stopped early after an independent data monitoring committee concluded that Opdivo provided a survival advantage over docetaxel, a standard chemotherapy, among patients with previously treated non-squamous non-small cell lung can...

Also read: FDA OKs 2nd gene therapy for blood cancer; 1st for adults

Read more

To category page

Loading...